Integrin signaling in cancer cell survival and chemoresistance.
Integrin signaling in cancer cell survival and chemoresistance.
复制标题
DOI：
10.1155/2012/283181
复制
发表时间：
2012
期刊：
影响因子：
--
通讯作者：
Vuori K
中科院分区：
文献类型：
--
作者：
Aoudjit F;Vuori K
对细胞凋亡和化疗的抵抗是癌细胞的标志，是癌症复发和患者复发的关键因素。细胞外基质（ECM）通过其受体整合素（integrins）成为促进癌细胞存活和化疗耐药的主要途径。过去十年的几项研究表明，ECM/整合素信号传导为各种类型的癌细胞抵抗多种化疗药物和抗体治疗提供了生存优势。在本文中，我们将讨论ECM/整合素信号传导如何保护肿瘤细胞免受药物诱导的凋亡的主要发现。我们还将讨论ECM在恶性t细胞存活和癌症干细胞抵抗中的潜在作用。了解整合素及其信号伙伴如何促进肿瘤细胞存活和化疗耐药将可能导致新的治疗策略和癌症治疗药物的发展。
Resistance to apoptosis and chemotherapy is a hallmark of cancer cells, and it is a critical factor in cancer recurrence and patient relapse. Extracellular matrix (ECM) via its receptors, the integrins, has emerged as a major pathway contributing to cancer cell survival and resistance to chemotherapy. Several studies over the last decade have demonstrated that ECM/integrin signaling provides a survival advantage to various cancer cell types against numerous chemotherapeutic drugs and against antibody therapy. In this paper, we will discuss the major findings on how ECM/integrin signaling protects tumor cells from drug-induced apoptosis. We will also discuss the potential role of ECM in malignant T-cell survival and in cancer stem cell resistance. Understanding how integrins and their signaling partners promote tumor cell survival and chemoresistance will likely lead to the development of new therapeutic strategies and agents for cancer treatment.